HighPoint Advisor Group’s Edwards Lifesciences EW Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-10,939
| Closed | -$933K | – | 782 |
|
|
2025
Q4 | $933K | Buy |
10,939
+489
| +5% | +$40.1K | 0.02% | 483 |
|
|
2025
Q3 | $813K | Buy |
10,450
+573
| +6% | +$44.8K | 0.04% | 292 |
|
|
2025
Q2 | $772K | Sell |
9,877
-1,739
| -15% | -$130K | 0.04% | 292 |
|
|
2025
Q1 | $886K | Sell |
11,616
-364
| -3% | -$26.1K | 0.05% | 258 |
|
|
2024
Q4 | $850K | Buy |
11,980
+577
| +5% | +$40.4K | 0.05% | 264 |
|
|
2024
Q3 | $770K | Sell |
11,403
-1,121
| -9% | -$81.4K | 0.04% | 274 |
|
|
2024
Q2 | $797K | Buy |
12,524
+9
| +0.1% | +$797 | 0.05% | 267 |
|
|
2024
Q1 | $1.06M | Sell |
12,515
-11
| -0.1% | -$924 | 0.07% | 213 |
|
|
2023
Q4 | $1.17M | Buy |
+12,526
| New | +$872K | 0.08% | 194 |
|
|
2022
Q2 | $2.21M | Buy |
+22,521
| New | +$2.33M | 0.24% | 81 |
|
|
2021
Q3 | $1.26M | Sell |
11,113
-193
| -2% | -$22K | 0.12% | 138 |
|
|
2021
Q2 | $1.17M | Buy |
11,306
+674
| +6% | +$63.5K | 0.12% | 143 |
|
|
2021
Q1 | $914K | Buy |
10,632
+1,664
| +19% | +$141K | 0.11% | 160 |
|
|
2020
Q4 | $769K | Buy |
8,968
+703
| +9% | +$58.3K | 0.09% | 177 |
|
|
2020
Q3 | $641K | Sell |
8,265
-485
| -6% | -$37.8K | 0.12% | 145 |
|
|
2020
Q2 | $604K | Buy |
8,750
+170
| +2% | +$12.1K | 0.13% | 140 |
|
|
2020
Q1 | $639K | Sell |
8,580
-7,236
| -46% | -$522K | 0.15% | 117 |
|
|
2019
Q4 | $1.28M | Sell |
15,816
-309
| -2% | -$24.1K | 0.26% | 77 |
|
|
2019
Q3 | $1.26M | Buy |
16,125
+7,467
| +86% | +$525K | 0.28% | 73 |
|
|
2019
Q2 | $559K | Sell |
8,658
-72
| -0.8% | -$4.35K | 0.13% | 137 |
|
|
2019
Q1 | $518K | Sell |
8,730
-9
| -0.1% | -$514 | 0.13% | 158 |
|
|
2018
Q4 | $515K | Buy |
8,739
+264
| +3% | +$13.4K | 0.14% | 157 |
|
|
2018
Q3 | $422K | Sell |
8,475
-243
| -3% | -$11.9K | 0.12% | 182 |
|
|
2018
Q2 | $405K | Buy |
8,718
+27
| +0.3% | +$1.26K | 0.11% | 197 |
|
|
2018
Q1 | $414K | Buy |
8,691
+2,394
| +38% | +$104K | 0.11% | 191 |
|
|
2017
Q4 | $267K | Sell |
6,297
-906
| -13% | -$33.3K | 0.08% | 238 |
|
|
2017
Q3 | $243K | Sell |
7,203
-12,819
| -64% | -$489K | 0.08% | 236 |
|
|
2017
Q2 | $775K | Hold |
20,022
| – | – | 0.25% | 97 |
|
|
2017
Q1 | $775K | Buy |
+20,022
| New | +$627K | 0.25% | 97 |
|
|
2016
Q4 | – | Sell |
-6,972
| Closed | -$211K | – | 280 |
|
|
2016
Q3 | $211K | Buy |
6,972
+1,059
| +18% | +$39.9K | 0.07% | 249 |
|
|
2016
Q2 | $223K | Buy |
+5,913
| New | +$202K | 0.08% | 243 |
|
Other funds holding EW
HighPoint Advisor Group's EW Position: Q1 2026 in Review
HighPoint Advisor Group sold out of Edwards Lifesciences (EW) in Q1 2026, closing a stake of 10,939 shares — an estimated $933K sold.
HighPoint Advisor Group first reported a position in EW in Q2 2016 and held it in 31 quarters. The position peaked at $2.21M in Q2 2022. 1,288 funds tracked by Wall St. Rank hold EW as of Q1 2026.
- HighPoint Advisor Group reported no remaining Edwards Lifesciences position as of Q1 2026 after selling out during the quarter.
- HighPoint Advisor Group sold 10,939 Edwards Lifesciences shares in Q1 2026, an estimated $933K.
- HighPoint Advisor Group first reported a position in Edwards Lifesciences in Q2 2016 and held it in 31 quarters.
- HighPoint Advisor Group's Edwards Lifesciences position peaked at $2.21M in Q2 2022.
- 1,288 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q1 2026.
Based on HighPoint Advisor Group's 13F filing for Q1 2026, filed 14 May 2026.